Astrazeneca Pharma India Profit & Loss Annual

BSE: 506820 | NSE: ASTRAZEN | ISIN: INE203A01020 | Sector: Major Drugs

6,455.40 +118.50 (1.87%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	1,295.53	1,002.97	805.60	813.56
Total Revenue	1,295.53	1,002.97	805.60	813.56
Costof Revenue Total	594.56	430.80	365.56	337.91
Gross Profit	700.97	572.17	440.04	475.65
Selling/ General/ Admin Expenses Total	332.90	397.16	343.64	326.58
Depreciation/ Amortization	14.94	16.26	16.95	20.13
Unusual Expense( Income)	-16.43	40.23	-	-
Other Operating Expenses Total	183.62	9.89	10.09	13.06
Total Operating Expense	1,109.59	894.34	736.24	697.68
Operating Income	185.94	108.63	69.36	115.88
Interest Inc( Exp) Net- Non- Op Total	-12.01	227.70	104.00	88.30
Other Net	34.80	0.21	0.46	0.21
Net Income Before Taxes	219.54	134.10	83.04	127.09
Provisionfor Income Taxes	58.03	34.81	21.44	33.79
Net Income After Taxes	161.51	99.29	61.60	93.30
Net Income Before Extra Items	161.51	99.29	61.60	93.30
Net Income	161.51	99.29	61.60	93.30
Total Adjustmentsto Net Income	0.02	-	-	-
Income Availableto Com Excl Extra Ord	161.51	99.29	61.60	93.30
Income Availableto Com Incl Extra Ord	161.51	99.29	61.60	93.30
Diluted Net Income	161.51	99.29	61.60	93.30
Diluted Weighted Average Shares	2.50	2.50	2.50	2.50
Diluted EPS Excluding Extra Ord Items	64.60	39.72	24.64	37.32
DPS- Common Stock Primary Issue	24.00	16.00	10.00	2.00
Diluted Normalized EPS	59.77	50.89	23.80	36.68
Gain( Loss)on Saleof Assets	-	24.90	28.20	21.70